Trial Profile
A Phase I Study of EGFRvIII Peptide Vaccination (CDX-110) After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Rindopepimut (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions
- 01 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2012 Planned end date changed from 1 Dec 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 13 Jul 2011 Actual initiation date (June 2011) added as reported by ClinicalTrials.gov.